Skip to main content

Day: November 21, 2022

Graybug and CalciMedica Enter into Definitive Merger Agreement

– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction....

Continue reading

InspireSemi Reports Third Quarter 2022 Financial Results and Provides Business Update

Company to Host Conference Call November 22, 2022 at 10:00 am ET VANCOUVER, British Columbia and AUSTIN, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) — Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that has built a technology foundation to deliver revolutionary performance, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. All financial information is presented in United States (“US”) Dollars unless otherwise indicated. “In the third quarter, we made substantial progress executing on our plan to become a game-changer in the accelerated computing solution industry,” said Ron Van Dell, CEO of InspireSemi. “We are in the final development stages of our anxiously awaited next-generation Thunderbird compute accelerator,...

Continue reading

Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update

Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022. Third Quarter HighlightsClosed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022. Continued enrollment in the Company’s Phase 2a study of AR-501 targeting cystic fibrosis (CF), conducted in collaboration with funding support from the Cystic...

Continue reading

Yamana Provides Notice of Record and Meeting Dates for the Proposed Transaction With Agnico and Pan American Silver and Declares Fourth Quarter Dividend

TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) — YAMANA GOLD INC. (TSX: YRI, NYSE: AUY, LSE: AUY) (“Yamana” or the “Company”) announces that it has filed the required notice setting the record and meeting dates in respect of the special meeting of shareholders to consider the previously announced proposed transaction (the “Proposed Transaction”) with Agnico Eagle Mines Limited and Pan American Silver Corp. (“Pan American Silver”). The record date, which is the date of record for determination of shareholders entitled to receive notice of and vote at the special meeting of shareholders, is set as December 14, 2022 and the special meeting of shareholders will be convened on January 31, 2023. Yamana has been advised that a Pan American Silver shareholder meeting is scheduled for the same day as the Company’s special meeting of shareholders. Further...

Continue reading

Fanhua Reports Third Quarter 2022 Unaudited Financial Results

— Operating Income for the Third Quarter of 2022 Grew 14.2% YOY — GUANGZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: FANH) (the “Company” or “Fanhua”), a leading independent financial services provider in China, today announced its unaudited financial results for the third quarter ended September 30, 20221. Financial Highlights for the Third Quarter of 2022(In thousands, except per ADS data) 2021Q3(RMB) 2022Q3(RMB) 2022Q3(US$) Change %Total net revenues 683,537 624,746 87,825 (8.6 )Operating income 28,163 32,165 4,522 14.2  Net income attributable to the Company’s shareholders 34,250 35,371 4,972 3.3  Diluted net income per ADS 0.64 0.66 0.09 3.1  Cash, cash equivalents and short-term investments and others (as of September 30, 2021 and 2022) 1,397,727 1,296,9262 182,319 (7.2 )Mr....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.